A recent study published in Nature Communications has identified two genomic regions associated with responses to statins, paving the way for tailored treatment plans. With over 40,000 research subjects involved, this meta-analysis demonstrates a significant impact of gene profiles on statin efficacy.
A new study by the Montreal Heart Institute found that high doses of fish oil supplements do not reduce atrial fibrillation, a common type of irregular heartbeat. The study also showed that fish oil supplements did not reduce inflammation or oxidative stress markers, which may explain their lack of efficacy.
A study has identified a dozen genetic mutations involved in changes to complete blood counts and the onset of severe biological disorders. The research used DNA from 6,796 people and found mutations in genes related to red and white blood cells and platelets.
Researchers at the Montreal Heart Institute have discovered a new compound that prevents valve deterioration and can even reverse aortic valve stenosis. The treatment could help avoid major complications of heart surgery and prevent heart failure and sudden death.
Researchers at the Montreal Heart Institute have discovered a blood protein that contributes to the early development of atherosclerosis. Angiopoietin-like protein 2 (angptl2) is found six times higher in subjects with coronary heart disease than healthy individuals, making it a potential early biomarker for the condition.
A clinical study found that treating psoriasis with adalimumab significantly decreased vascular inflammation, a major risk factor for cardiovascular disease. The study also showed a 51% decrease in C-reactive protein levels among treated patients, compared to a 2% decrease in the control group.
A new medication, ivabradine, has been shown to reduce both heart rate and volume in patients with cardiac insufficiency, leading to a significant reduction in mortality and hospitalizations. This discovery holds promise for a new approach to treating this condition.
A Montreal Heart Institute study found that ivabradine significantly improves left ventricular diastolic dysfunction and reduces cardiac fibrosis in rabbits with cholesterol-enriched diets. The results suggest that ivabradine may be an effective treatment for patients with diastolic heart failure.
The study found that participants lost an average of 5.5% of their body mass, reduced waist circumference by 5.15%, and increased effort capacity by 15%. The program also showed a decrease in bad cholesterol and increase in good cholesterol.
A new trial shows that standard-dose clopidogrel is as effective as double the dose for preventing cardiovascular events in patients with high on-treatment platelet reactivity. Researchers argue that a personalized approach to antiplatelet therapy may be more beneficial, warranting further investigation.